Experimental and Investigational Treatments: Why Insurers Often Say No

Why Health Plans Exclude Experimental Treatments

When a health plan says it won't cover a treatment because it is "experimental" or "investigational," it is invoking one of the broadest and most consequential exclusions in all of insurance. Understanding why insurers use this exclusion — and how they define it — is the first step to knowing whether you can fight back.

At its core, insurance is a financial product built on predictability. Insurers calculate premiums by estimating the probability and cost of covered claims. Treatments with uncertain outcomes introduce a variable they cannot price reliably. If a new therapy might work brilliantly for 20% of patients and fail entirely for the other 80%, covering it broadly exposes the insurer to unpredictable losses. That uncertainty is the engine behind the experimental exclusion.

There is also a more legitimate public health rationale. Paying for treatments before adequate evidence exists can steer patients toward unproven therapies and away from established care. Some argue the exclusion protects patients as much as it protects insurer balance sheets — though this argument carries less weight when the excluded treatment is a patient's last remaining option.

To understand exactly how exclusions work in the language of a policy document, see our explainer on the anatomy of an insurance exclusion. The experimental treatment exclusion typically appears in the same section as other broad categorical denials — and like them, it is deliberately written with wide latitude.

How Insurers Define 'Experimental' — and Why It's Contested

Here is where things get complicated for patients: there is no single, universally accepted definition of what makes a treatment experimental. Each insurer writes its own criteria into its Evidence of Coverage or Summary Plan Description. While the criteria share common elements, the specific thresholds differ — and that variation can mean the difference between a $200,000 treatment being covered or not.

The Standard Multi-Factor Test

Most commercial insurers evaluate a treatment against some combination of the following factors:

• FDA status: Has the treatment received FDA approval or clearance, and for which specific indication?
• Clinical evidence: Are there published, peer-reviewed studies — ideally randomized controlled trials — demonstrating safety and effectiveness?
• Professional society guidelines: Do major medical specialty organizations (such as the American Society of Clinical Oncology or the American Heart Association) endorse the treatment for the condition in question?
• Medicare coverage: Has the Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination (NCD) approving the treatment?
• Widespread acceptance: Is the treatment recognized by the general medical community as standard of care?

A treatment that fails even one of these factors may be classified as investigational. And critically, meeting most of them doesn't automatically guarantee coverage — the insurer retains discretion to weigh these factors as it sees fit.

The Off-Label Use Problem

One of the most misunderstood situations involves off-label drug use. When the FDA approves a drug, it approves it for a specific indication — a particular disease or condition. Physicians frequently prescribe drugs for conditions outside that approved indication, based on clinical judgment and emerging research. This practice is entirely legal and medically common.

However, insurers often treat off-label use as investigational, even when the drug itself is FDA-approved and the off-label application is widely practiced. Oncology patients frequently encounter this issue: a chemotherapy drug approved for one cancer type may be the best available option for a related cancer, but an insurer may deny it as experimental in the second context.

This is one of the reasons experimental treatment denials touch so many cancer patients in particular. The disease landscape evolves faster than regulatory approvals, and the gap between emerging clinical evidence and formal coverage decisions can span years.

Reading the Exclusion in Your Own Policy

Before you can challenge a denial or plan your care, you need to know exactly what your policy says. Pull out your Evidence of Coverage, Summary Plan Description, or Certificate of Insurance — whichever document governs your specific plan — and look for a section titled something like "General Exclusions," "Services Not Covered," or "Coverage Limitations."

The experimental treatment exclusion will typically contain language similar to: "Services, supplies, or charges that are experimental, investigational, or unproven, including but not limited to those that do not meet the plan's medical review criteria at the time services are rendered."

Pay attention to two things in that language. First, the phrase "at the time services are rendered" — this means even if a treatment later becomes standard of care, the plan may still deny it if it was classified as experimental on the date you received it. Second, the reference to "the plan's medical review criteria" signals that there are internal documents — sometimes called Coverage Determination Guidelines or Medical Policy Bulletins — that spell out exactly how the plan evaluates any given treatment.

You have the right to request those internal guidelines. Ask for the specific Clinical Coverage Policy or Medical Policy that applies to your denied treatment. This document is your roadmap for the appeal — it tells you exactly what evidence the plan requires, and it gives you the framework to argue that your treatment meets those standards.

For a broader look at what is typically missing from standard health plans and why, our article on what most health plans don't cover provides useful context alongside the experimental treatment exclusion.

“The word 'experimental' in an insurance policy is not a medical judgment — it is a coverage judgment. Those two things sound the same but they operate on entirely different logic, and patients who understand the difference are far better equipped to appeal.”

— Sabrina Corlette, Research Professor, Georgetown University Center on Health Insurance Reforms

What Your Rights Look Like: Appeals and External Review

A denial is not the end of the road. Federal law and most state laws give you a structured process to challenge coverage decisions, and the experimental treatment exclusion is not immune to appeal. Here is how the process works, step by step.

Step 1: Internal Appeal

You must first exhaust the insurer's internal appeals process. When you receive a denial, the Explanation of Benefits (EOB) or denial letter must include the specific reason for denial and instructions for filing an appeal. You typically have 180 days from the date of denial to file an internal appeal under ACA rules, though this varies by plan type.

Your appeal package should include:

1. A letter from your treating physician explaining medical necessity and citing relevant clinical evidence
2. Copies of peer-reviewed studies supporting the treatment's effectiveness for your specific condition
3. Any applicable professional society clinical guidelines endorsing the treatment
4. The plan's own Coverage Policy document, with annotations showing how your treatment meets its stated criteria
5. Your medical records documenting why alternative, covered treatments are insufficient or contraindicated

Step 2: External Independent Review

If your internal appeal is denied, you have the right to request an External Independent Review in most states. An independent organization — not affiliated with the insurer — reviews your case and makes a binding determination. Under the ACA, this right applies to most non-grandfathered health plans for medical necessity and experimental treatment denials.

External review is one of the most powerful tools available to patients. Studies show that patients win a meaningful percentage of external reviews, particularly in cancer-related experimental treatment cases. Do not skip this step.

State Protections: An Important Variable

If you have a state-regulated plan (individual or fully-insured small-group coverage), your state's insurance commissioner may have enacted additional protections. Some states require coverage for off-label drug use in specific circumstances, particularly for cancer treatment. Others mandate coverage of clinical trial costs beyond what the ACA requires. State rules vary enormously — contact your state insurance commissioner's office or a patient advocate to learn what applies to you.

Note that if you receive coverage through a large employer's self-funded plan, ERISA federal law generally preempts state insurance regulations. This matters because ERISA significantly limits your remedies if your appeal is denied, which is one reason understanding how insurers respond to risk is so important before you reach the point of a dispute.

Alternative Pathways When Coverage Is Denied

Sometimes an appeal is not successful, or the timeline doesn't match the urgency of your medical situation. In those cases, there are several parallel pathways worth exploring.

Clinical Trials

If the treatment you're seeking is in active clinical trials, enrollment may give you access to it at no cost. Trial sponsors — pharmaceutical companies, research universities, government agencies — typically cover the cost of the investigational drug or device. Under the ACA, your health plan must cover routine care costs associated with your participation in qualifying trials: office visits, imaging, lab work, and management of side effects are typically covered even though the experimental intervention itself is not.

The National Institutes of Health maintains ClinicalTrials.gov, a searchable database of every registered trial in the United States. Your oncologist or specialist can help you evaluate whether any open trials are appropriate for your situation.

Manufacturer Patient Assistance Programs

Pharmaceutical and medical device manufacturers sometimes offer compassionate use or expanded access programs that provide investigational treatments outside of formal clinical trials. These programs are FDA-regulated and typically reserved for patients with serious or life-threatening conditions who have no comparable alternatives. Your physician must apply on your behalf.

Second Opinions and Peer-to-Peer Reviews

Most plans allow your physician to request a peer-to-peer review — a direct conversation between your treating doctor and the insurer's medical reviewer. This is separate from the formal appeals process and can sometimes resolve a denial faster. It gives your physician the opportunity to present clinical nuances that a written denial review may have missed.

Patient Advocates and Legal Counsel

Professional patient advocates — often nurses or social workers with insurance expertise — can navigate the appeals process on your behalf, particularly if your health is preventing you from managing the paperwork. In complex cases, an attorney specializing in health insurance law can assess whether litigation or a regulatory complaint to your state insurance commissioner is warranted.

For patients with significant pre-existing conditions or complex health histories, our overview of options for high-risk insurance applicants explores the broader coverage landscape beyond standard commercial plans.

The Bigger Picture: Evidence, Ethics, and the Ongoing Debate

The experimental treatment exclusion sits at the intersection of medicine, insurance economics, and ethics. Reasonable people disagree about where the line between "emerging evidence" and "established care" should be drawn — and who should draw it.

Critics of the current system argue that insurers set the evidentiary bar too high, particularly in oncology, rare diseases, and pediatric medicine, where randomized controlled trial data is often limited by definition. Advocates for insurers respond that paying for treatments without adequate evidence wastes healthcare dollars that could fund care with proven benefits and may expose patients to harm.

What both sides acknowledge is that the process is opaque. Patients are often denied coverage without receiving a clear explanation of which specific criterion their treatment failed to meet. When policy limits and exclusions are applied without transparency, patients cannot effectively advocate for themselves.

Legislative pressure has produced some reforms. The ACA's clinical trials provision was a significant step. Several states have enacted laws requiring coverage for off-label cancer treatments. And CMS's Coverage with Evidence Development pathway represents an attempt to fund treatments while simultaneously generating the evidence needed to evaluate them properly.

Still, the fundamental tension remains: medicine moves faster than coverage policy. Until that gap closes, patients will continue to find themselves denied coverage for treatments their physicians believe could help them — and the process of understanding, appealing, and navigating around those denials will remain an essential skill for anyone facing a serious diagnosis.

If you want a deeper understanding of how insurers communicate these decisions and what you can do proactively, our guide on communicating with your insurer about policy exclusions offers practical strategies for every stage of the process.